SpliceBio
Sílvia Frutos has a diverse work experience in the biotechnology and scientific research field. Their most recent position was as the CTO at Splice Bio, where they started in September 2020. Prior to that, they were a co-founder and COO of ProteoDesign from May 2014 until August 2020. Sílvia also worked as a postdoctoral fellow at The Rockefeller University from 2007 to April 2014. Sílvia's career in research began as a PhD student at the Parc Cientific Barcelona - Science Park of Barcelona PCB, Institute for Research in Biomedicine (IRB), and Parc Científic de Barcelona (PCB) from 2002 to 2007.
Sílvia Frutos earned their PhD in Chemistry from the Universitat de Barcelona, completing their studies between 2002 and 2006.
This person is not in any teams
This person is not in any offices
SpliceBio
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.